The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| GBIO | -75.69% | -98.02% | -54.34% | -98% |
| S&P | +19.61% | +98.99% | +14.75% | +125% |
Generation Bio Co. is a genetic medicine company, which focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. Its non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA, a novel cell-targeted lipid nanoparticle delivery system, or ctLNP, and an established, scalable capsid-free manufacturing process. The company was founded by Mark D. Angelino, Jason P. Rhodes, and Robert M. Kotin in 2016 and is headquartered in Cambridge, MA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.77M | -81.3% |
| Gross Profit | -$0.37M | -113.0% |
| Gross Margin | -48.24% | -117.4% |
| Market Cap | $21.55M | -88.5% |
| Market Cap / Employee | $0.19M | 0.0% |
| Employees | 115 | -33.9% |
| Net Income | -$20.92M | -2.4% |
| EBITDA | -$21.26M | -3.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $49.09M | 72.3% |
| Accounts Receivable | $0.26M | -80.9% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $75.57M | -11.4% |
| Short Term Debt | $9.75M | 13.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -32.57% | 14.7% |
| Return On Invested Capital | -43.30% | 56.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$17.29M | 19.8% |
| Operating Free Cash Flow | -$16.83M | 21.9% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.58 | 0.82 | 0.37 | 0.40 | -71.95% |
| Price to Sales | 8.87 | 3.56 | 1.11 | 1.01 | -92.90% |
| Price to Tangible Book Value | 14.28 | 6.77 | 3.15 | 2.92 | -79.41% |
| Enterprise Value to EBITDA | -4.75 | 1.14 | 3.12 | 1.63 | -151.47% |
| Return on Equity | -86.5% | -91.0% | -70.1% | -85.4% | -0.30% |
| Total Debt | $93.78M | $93.56M | $87.58M | $85.32M | -9.19% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
